The other detrimental effect of the release of IL-17 in adipose tissue is long-term reduced insulin sensitivity, which could be responsible for the development of diabetes mellitus type II as a part of metabolic syndrome [29,30]. Here, INS is linked to type 2 diabetes mellitus.